causal
Big pharma as forced buyer of startups
Over the past 20 years big pharma divested most internal early-stage R&D and pivoted to buying startups from private markets or public biotechs, creating a forced buyer spending $20 to $30 billion a year and a structural opportunity for venture capital because patent cliffs require replacing expiring products.
causalpending
Speaker
D.A.Evidence Quote
“all of the big pharma companies almost to a one have divested from internal research and development, especially at the early stages”
Created: 11/17/2026, 5:03:43 PM
Your notes
Loading notes...